Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Go back to Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)| (NASDAQ: INTS) | Delayed: 4.10 +0.10 (2.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.00 | 52 Week High | $ | |||
| Open | $3.99 | 52 Week Low | $ | |||
| Day High | $4.11 | P/E | N/A | |||
| Day Low | $3.99 | EPS | $ | |||
| Volume | 4,494 | |||||
